Clinical Trial

A Study to Assess the Safety of ARGX-124 in Healthy Volunteers

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study aims to assess the safety of ARGX-124 in healthy adults. Another aim is to measure the amount of ARGX-124 in the blood over time to learn how it acts and moves in the body and how the immune system responds to it. Participants will remain in the study for up to approximately 23 weeks.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-22.
Status change: Not Yet Recruiting → Recruiting 2026-03-04
Trial Details
NCT Number NCT07377396
Lead Sponsor argenx
Conditions Healthy Volunteers
Enrollment 104 participants
Start Date 2026-01-26
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-06